Compare TFSL & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TFSL | ELVN |
|---|---|---|
| Founded | 1938 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.2B |
| IPO Year | 2006 | 2020 |
| Metric | TFSL | ELVN |
|---|---|---|
| Price | $16.06 | $46.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 14 |
| Target Price | $18.00 | ★ $74.33 |
| AVG Volume (30 Days) | 673.9K | ★ 1.4M |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 7.81% | N/A |
| EPS Growth | ★ 14.29 | 3.17 |
| EPS | ★ 0.27 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.65 | N/A |
| Revenue Next Year | $2.84 | N/A |
| P/E Ratio | $60.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.21 | $14.79 |
| 52 Week High | $19.49 | $62.32 |
| Indicator | TFSL | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 37.46 | 51.53 |
| Support Level | $16.04 | $44.18 |
| Resistance Level | $16.20 | $47.88 |
| Average True Range (ATR) | 0.32 | 2.28 |
| MACD | -0.03 | 0.31 |
| Stochastic Oscillator | 3.63 | 41.92 |
TFS Financial Corp is the holding company for the Third Federal Savings and Loan Association of Cleveland. The company's ownership in the savings and loan association is its primary business activity. The association's principal business consists of originating and servicing residential real estate mortgage loans and attracting retail savings deposits. It does so by offering products with competitive rates and yields. The company also operates Third Capital, a wholly owned subsidiary that serves as a holding company or as an investor in vehicles such as private equity funds. Third Capital has interests in lease transactions of commercial buildings, title agencies providing escrow and settlement services, and reinsurance of private mortgage insurance on residential loans.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.